This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Series A round by Biohaven brings in $80mm for CNS pipeline development; later adds $20mm
24 Apr 2017
Biohaven Pharmaceuticals Holding Co. Ltd. (orphan neurologic disease candidates) raised $80mm in a Series A preferred round led by Venrock, which was joined by RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Litmore Capital, and board members John W. Childs and Greg Bailey, MD (who is also the company’s SVP, business development). Cowen & Co. and William Blair were co-placement agents. Prior to this round, the company brought in about $20mm in financing.
In Vitro Diagnostics
Therapeutic Drug Monitoring
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?